New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
15:21 EDTPRKR, GLPW, FF, DTSI, KYTH, GALENotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Kythera Biopharmaceuticals (KYTH), consensus (69c); FutureFuel (FF), consensus 23c; Parkervision (PRKR), one estimate (6c); DTS Inc. (DTSI), consensus 49c; Global Power Equipment (GLPW), consensus 37c; Galena Biopharma (GALE), consensus (9c)
News For KYTH;FF;PRKR;DTSI;GLPW;GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
10:36 EDTPRKRParkerVision says appeals court affirms district court noinfringement decision
Subscribe for More Information
09:54 EDTPRKRParkerVision loses appeal of Qualcomm patent ruling
Shares of ParkerVision (PRKR) plunged 50% before being halted for trading after an appeals court affirmed a lower court ruling in the company's patent infringement suit with Qualcomm (QCOM). At trial, ParkerVision accused 19 Qualcomm products of infringing its asserted claims. The district court found that the accused products did not practice the limitation that recites “generating a lower frequency signal,” which is present in each asserted claim. The court held that ParkerVision’s infringement expert conceded that in the accused products the baseband signal was created before, or “upstream from,” the storage capacitor. That concession, the court concluded, was fatal to ParkerVision’s claim under the “generating” limitation. Second, the court concluded that Qualcomm’s “50% duty cycle” products did not practice the “sampling” limitation, which is found in claims 27, 82, 90, and 91 of the ’518 patent, and in claim 2 of the ’371 patent. In a new ruling, the U.S. Court of Appeals for the Federal Circuit agreed with the district court on both grounds.
09:47 EDTPRKRParkerVision trading halted, pending news
Subscribe for More Information
09:31 EDTPRKRCourt rules Qualcomm did not infringe ParkerVision patents, Bloomberg reports
Subscribe for More Information
July 29, 2015
07:15 EDTGALEGalena announces U.S. product launch of Zuplenz Oral Soluble Film
Subscribe for More Information
July 27, 2015
16:46 EDTKYTHAllergan, KYTHERA announce early termination of HSR waiting period
Subscribe for More Information
09:03 EDTKYTHKYTHERA announces Health Canada authorization of Belkyra
KYTHERA Biopharmaceuticals announced it has received authorization from Health Canada to market Belkyra "for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.” Belkyra is a non-surgical treatment for improving the appearance and profile of submental fullness—more commonly known as “double chin,” a facial aesthetic condition that affects both women and men. Belkyra was recently launched in the U.S. under the brand name Kybella.
July 21, 2015
16:18 EDTPRKRParkerVision and RFMW signs worldwide distribution agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use